Last reviewed · How we verify

NCT01398020

Oral 2L Bi-PegLyte Versus 4L PegLyte Regimen for Outpatient Colonic Preparation: A Randomized, Non-Inferiority Open Trial

Completed NA Last updated 17 September 2013
What this trial tests

NA trial testing Standard Bowel Prep in Efficacy of Bowel Preparation in 318 participants. Completed in 1 September 2013.

Timeline
1 July 2011
Primary endpoint
1 September 2012
1 September 2013

Quick facts

Lead sponsorUniversity of British Columbia
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Enrollment318
Start date1 July 2011
Primary completion1 September 2012
Estimated completion1 September 2013
Sites1 location across Canada

Drugs / interventions tested

Conditions studied

Sponsor

University of British Columbia

Who can join

19 and older, any sex, with Efficacy of Bowel Preparation or Ease of Bowel Preparation and Patient Tolerability. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Sponsor's own description

The investigators wish to compare the efficacy and patient tolerability of a preparation consisting of 2L Bi-Peglyte plus 15mg of bisacodyl vs the standard preparation of 4L Peglyte. The investigators hypothesize that 2L Bi-Peglyte with 15mg bisacodyl will show higher efficacy and tolerability.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Standard Bowel Prep

Trials testing the same drug.

Other University of British Columbia trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01398020.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing